Comparative analysis of vibration-controlled transient elastography and EUS-shear wave elastography for liver stiffness measurement in cirrhosis
- PMID: 40385964
- PMCID: PMC12080694
- DOI: 10.1097/eus.0000000000000114
Comparative analysis of vibration-controlled transient elastography and EUS-shear wave elastography for liver stiffness measurement in cirrhosis
Abstract
Background and objectives: Chronic liver inflammation leads to fibrosis and cirrhosis. To avoid portal hypertension-related complications, fibrosis' early detection is imperative. Biopsy remains the gold standard, but magnetic resonance elastography (MRE) and EUS-guided elastography are noninvasive procedures currently used for liver stiffness measurement (LSM). Two-dimensional EUS-guided shear-wave elastography (EUS-SWE) represents a more-every-day used technique.The aim of this study is to correlate LSM determined by vibration-controlled transient elastography (VCTE) and EUS-SWE and determine the measurements' accuracy in diagnosing cirrhosis.
Methods: A single-center, nested case-control study was performed between March 2020 and November 2021. Patients were classified into 2 study groups: the cirrhosis group and the control group. Patients from both groups underwent VCTE and EUS-SWE for LSM. A P value < 0.05 was considered statistically significant.
Results: Of the 59 participants included (mean age 63.5 years; 71.1% female), 29 had cirrhosis (49.15%) and 30 were controls (50.84%). In cirrhosis patients, liver fibrosis (F) was staged as F3-4 by VCTE in 82.8%, with a median LSM of 17.8 kPa; through EUS-SWE, 27 kPa in the right hepatic lobe (RHL) and 25 kPa in the left hepatic lobe (LHL). Controls fibrosis was staged as F0-2 by VCTE in 30/30 (100%), with a median LSM of 4.6 kPa (P < 0.001); through EUS-SWE, 5.6 kPa in the RHL (P < 0.001) and 6.5 kPa in the LHL (P < 0.001). The observed agreement was 91.5% for VCTE, 93.2% for RHL-EUS-SWE, and 96.6% for LHL-EUS-SWE. The AUROCs for EUS-SWE and VCTE were over 0.95.
Conclusions: VCTE and EUS-SWE are comparable techniques for diagnosing cirrhosis; however, EUS-SWE had a higher agreement than VCTE, especially in LHL assessment.
Keywords: EUS; Elastography; Fibrosis; Liver cirrhosis.
Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc on behalf of Scholar Media Publishing.
Conflict of interest statement
Carlos Robles-Medranda is a key opinion leader and consultant for Pentax Medical, Steris, Micro-tech, G-Tech Medical Supply, CREO Medical, EndoSound, and mdconsgroup. The other authors have nothing to disclose.
Figures



Similar articles
-
Comparative accuracy of endosonographic shear wave elastography and transcutaneous liver stiffness measurement: a pilot study.Gastrointest Endosc. 2023 Jan;97(1):35-41.e1. doi: 10.1016/j.gie.2022.08.035. Epub 2022 Aug 29. Gastrointest Endosc. 2023. PMID: 36049537
-
Reproducibility of EUS-guided shear wave elastography for assessment of hepatic fibrosis: a prospective pilot cohort study.Gastrointest Endosc. 2025 Mar;101(3):659-662. doi: 10.1016/j.gie.2024.10.064. Epub 2024 Nov 8. Gastrointest Endosc. 2025. PMID: 39521092
-
Agreement Between 2-Dimensional Shear Wave and Transient Elastography Values for Diagnosis of Advanced Chronic Liver Disease.Clin Gastroenterol Hepatol. 2020 Dec;18(13):2971-2979.e3. doi: 10.1016/j.cgh.2020.04.034. Epub 2020 Apr 26. Clin Gastroenterol Hepatol. 2020. PMID: 32348907
-
Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD.J Clin Exp Hepatol. 2022 Jan-Feb;12(1):174-179. doi: 10.1016/j.jceh.2021.08.002. Epub 2021 Aug 8. J Clin Exp Hepatol. 2022. PMID: 35068797 Free PMC article. Review.
-
THE ROLE OF ELASTOGRAPHY IN CLINICALLY SIGNIFICANT PORTAL HYPERTENSION.Arq Gastroenterol. 2023 Oct-Dec;60(4):525-535. doi: 10.1590/S0004-2803.230402023-64. Arq Gastroenterol. 2023. PMID: 38018555 Review.
Cited by
-
The application of EUS-guided portal pressure gradient measurement with concomitant EUS-liver elastography and EUS-guided liver biopsy in patients with chronic liver disease: a single center experience.Therap Adv Gastroenterol. 2025 Jul 30;18:17562848251359015. doi: 10.1177/17562848251359015. eCollection 2025. Therap Adv Gastroenterol. 2025. PMID: 40756180 Free PMC article.
References
-
- Eskridge W, Vierling JM, Gosbee W, Wan GA, Hyunh M-L, Chang HE. Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a population-based risk factor assessment using vibration controlled transient elastography (VCTE). PloS One 2021;16(11):e0260320. - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous